Translational Development Acquisition Corp.
NASDAQ:TDACShell Companies
-$0.01 today
- Market cap
- $267.99M
- Beta
- 0.01
- P/E (TTM)
- 29.8
- EPS (TTM)
- $0.36
Volume 0.47M
Average 0.10M
TDAC Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Translational Development Acquisition Corp.NASDAQ: TDAC
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 320.87K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Cost of Revenue vs competitors
How TDAC compares with its peers on the latest reported figures
- TDAC's LTM Mar 2026 cost of revenue of $0 is the 2nd highest of the 7 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2022 | $1.92M | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
MACIMelar Acquisition Corp. I | LTM Mar 2026 | $0 | — | — | — |
NTWONewbury Street II Acquisition Corp | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding TDAC) | $0 | -100.0% | — | — | |
Competitors are the stored peer set for TDAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.07M | 0 |
| Cost of Revenue | 0 | 0 | 320.87K | 0 |
| Gross Profit | 0 | 0 | 744.92K | 0 |
| Gross Margin | — | — | 69.9% | — |
| Research & Development | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 70.66K | 485.55K | 196.36K | 944.54K |
| Operating Expenses | 70.66K | 485.55K | 196.36K | 944.54K |
| Depreciation & Amortization | 70.66K | 0 | 0 | 0 |
| EBITDA | 0 | (485.55K) | (71.01K) | (944.54K) |
| EBITDA Margin | — | — | -6.7% | — |
| Operating Income | (70.66K) | (485.55K) | (196.36K) | (944.54K) |
| Operating Margin | — | — | -18.4% | — |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 508.56K | 0 |
| Other Income / Expenses | 0 | 0 | 125.35K | 7.31M |
| Income Before Tax | (70.66K) | (485.55K) | (71.01K) | 6.36M |
| Pre-Tax Margin | — | — | -6.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (70.66K) | (485.55K) | (71.01K) | 6.36M |
| Net Margin | — | — | -6.7% | — |
| EPS (Basic) | (0.02) | (0.12) | (0.02) | 0.37 |
| EPS (Diluted) | (0.02) | (0.12) | (0.02) | 0.37 |
| Weighted Avg Shares | 4.05M | 4.05M | 4.05M | 17.25M |
| Weighted Avg Shares (Diluted) | 4.05M | 4.05M | 4.05M | 17.25M |
Translational Development Acquisition Corp.
NASDAQ:TDAC
Intrinsic Alpha fair value
Locked
Current Price
$10.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.